Thus, intranasal delivery of dimeric or secretory DXP-604 IgA in combination with other IgA antibodies directly to the site of infection may be an effective approach to achieve immediate protection against SARS-CoV-2 infection, which is needed at a small window for intervention, such as prevention in high-risk settings or postexposure prophylaxis. The gene discussed is CD79A; the disease is infection.